The three goals of the Cancer Therapeutic Program are: 1) to enhance and facilitate programmatic and interprogrammatic interaction and collaboration between basic scientists and clinical investigators in cancer therapeutics;2) to promote the discovery, development, and application of novel therapeutic approaches;and 3) to develop translational and laboratory-based clinical investigations of new therapeutic agents and new therapeutic approaches. These goals are achieved through three Research Themes. Theme 1 is focused on technology development for target identification and drug discovery, with the goal of applying these new technologies (such as combinatorial chemistry, medicinal chemistry, computational biology, structural biology, nanotechnology, and high-throughput assays) to specific drug development projects in theme 2. For example, in theme 2, we are developing: cancer cell surface targeting ligands, novel targeting nanocarriers for cancer drug delivery and imaging, tyrosine kinase inhibitors, and nanoparticles for cancer vaccine and immunotherapy. In Theme 3, we use a collaborative group of molecular biologists, translational scientists, pharmacologists, and clinical investigators to facilitate the design and conduct of laboratory-driven clinical investigations. In view of the preclinical expertise in drug discovery and drug development available within the Program, there is great potential to translate promising new therapeutic leads into clinical trials and associated laboratory correlative studies. One example of such translation is the development of novel nanoformulations of paclitaxel soon to be tested in human. Furthermore, the expertise represented within this group of investigators provides a conduit for acquisition of new therapeutic agents from the NCI or industry. Providing a platform for clinical trials are specific project areas in clinical investigation and translational studies, including drug development awards (N01, U01, U10) and investigator-initiated trials. The program has 46 members from 13 different departments at UC Davis and 1 department at LLNL. It has 25 NCl-funded projects for $3.9 million ADC (total peer-reviewed funding, $8.8 million ADC). Of the 728 publications for the last funding period, 44% are inter-programmatic and 29% are intra-programmatic.

Public Health Relevance

Through the three interactive research themes, investigators from the Cancer Therapeutic Program will translate promising new therapeutic leads into clinical trials and associated laboratory correlative studies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA093373-12
Application #
8743641
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
12
Fiscal Year
2014
Total Cost
$22,224
Indirect Cost
$7,745
Name
University of California Davis
Department
Type
DUNS #
047120084
City
Davis
State
CA
Country
United States
Zip Code
95618
Braithwaite, Dejana; Miglioretti, Diana L; Zhu, Weiwei et al. (2018) Family History and Breast Cancer Risk Among Older Women in the Breast Cancer Surveillance Consortium Cohort. JAMA Intern Med 178:494-501
Unger, Jakob; Sun, Tianchen; Chen, Yi-Ling et al. (2018) Method for accurate registration of tissue autofluorescence imaging data with corresponding histology: a means for enhanced tumor margin assessment. J Biomed Opt 23:1-11
Wang, Guobao; Corwin, Michael T; Olson, Kristin A et al. (2018) Dynamic PET of human liver inflammation: impact of kinetic modeling with optimization-derived dual-blood input function. Phys Med Biol 63:155004
Winer, Rachel L; Tiro, Jasmin A; Miglioretti, Diana L et al. (2018) Rationale and design of the HOME trial: A pragmatic randomized controlled trial of home-based human papillomavirus (HPV) self-sampling for increasing cervical cancer screening uptake and effectiveness in a U.S. healthcare system. Contemp Clin Trials 64:77-87
Withers, Sita S; Skorupski, Katherine A; York, Daniel et al. (2018) Association of macrophage and lymphocyte infiltration with outcome in canine osteosarcoma. Vet Comp Oncol :
Floc'h, Nicolas; Martin, Matthew J; Riess, Jonathan W et al. (2018) Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions. Mol Cancer Ther 17:885-896
Shih, Tsung-Chieh; Liu, Ruiwu; Wu, Chun-Te et al. (2018) Targeting Galectin-1 Impairs Castration-Resistant Prostate Cancer Progression and Invasion. Clin Cancer Res 24:4319-4331
Weiss, Robert H (2018) Metabolomics and Metabolic Reprogramming in Kidney Cancer. Semin Nephrol 38:175-182
Hegde, John V; Shaverdian, Narek; Daly, Megan E et al. (2018) Patient-reported quality-of-life outcomes after de-escalated chemoradiation for human papillomavirus-positive oropharyngeal carcinoma: Findings from a phase 2 trial. Cancer 124:521-529
Arun, Adith S; Tepper, Clifford G; Lam, Kit S (2018) Identification of integrin drug targets for 17 solid tumor types. Oncotarget 9:30146-30162

Showing the most recent 10 out of 836 publications